Ganovo (Danoprevir) – HCV | HongKong DengYue Medicine

  • Generic Name/Brand Name: Danoprevir / Ganovo
  • Indications: HCV
  • Dosage Form: Capsule
  • Specification: 100 mg
Category: Tags: , ,

Ganovo Application Scope

Ganovo is an orally administered hepatitis C virus (HCV) NS3/4A protease inhibitor. It was the first domestically developed direct-acting antiviral (DAA) for HCV approved in China.

ganovo

Characteristics

  • Ingredients: Danoprevir

  • Properties: Danoprevir is a potent inhibitor of the HCV NS3/4A protease, which is essential for viral replication.

  • Packaging Specification: Typically supplied in blister packs containing 100 mg film-coated tablets.

  • Storage: Store in a cool, dry place away from direct sunlight.

  • Expiry Date: ​Refer to the packaging for the specific expiration date.

  • Executive Standard: Manufactured in compliance with Good Manufacturing Practices (GMP)

  • Approval Number: Approved by the National Medical Products Administration (NMPA) of China

  • Date of Revision: Refer to the latest prescribing information leaflet for the date of revision.

  • Manufacturer: Ascletis Pharma Inc., China.

Guidelines for the Use of Ganovo

  • Dosage and Administration:

    • The recommended dosage is 100 mg taken orally twice daily

    • In combination with other antiviral agents such as ritonavir and peginterferon alfa-2a plus ribavirin

    • Depending on the specific treatment regimen

 

  • Adverse Reactions:

    • Common side effects may include fatigue, headache, nausea, and diarrhea.

    • Serious adverse reactions are rare but can include liver enzyme elevations.

  • Contraindications: Contraindicated in patients with known hypersensitivity to danoprevir or any component of the formulation.

  • Precautions:

    • Use with caution in patients with moderate to severe hepatic impairment.

    • Regular monitoring of liver function tests is recommended during treatment.

Ganovo Interactions

  • Drug Interactions:

    • Danoprevir is metabolized by the CYP3A4 enzyme

    • Co-administration with strong CYP3A4 inhibitors or inducers may affect drug levels

    • It is often administered with ritonavir to boost its plasma concentration

    • Careful consideration should be given when combining with other medications metabolized by CYP3A4

Note:

  • If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
  • It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.
Contact Us
Contact Form Demo